Good Penny Stocks To Buy Now? 7 Under $1 To Watch This Week
- Penny stocks to watch under $1 right now. The post Good Penny Stocks To Buy Now?
- 10/20/2022
|
Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure
- Adamis Pharmaceuticals recently provided an update on Tempol's Phase II/III COVID-19 trial, which revealed the interim did not demonstrate statistical significance of its primary endpoint. The DSMB has recommended the company halt the trial. The company believes vaccination and the Omicron variant might have influenced the outcomes.
- 09/30/2022
|
Adamis Pharmaceuticals Corporation (ADMP) CEO David J. Marguglio on Q2 2022 Results - Earnings Call Transcript
- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Robert Uhl - Managing Director, ICR Westwicke David J. Marguglio - Chief Executive Officer David Benedicto - Chief Financial Officer Ron Moss - Chief Medical Officer Conference Call Participants Operator Greetings and welcome to the Adamis Pharmaceuticals' Second Quarter 2022 Financial Results Conference Call.
- 08/11/2022
|
Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update
- SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Wednesday, August 10, 2022 at 1:30 p.m. Pacific Time to discuss its financial and operating results for the second quarter 2022 as well as provide a corporate update. The company's press release concerning its second quarter 2022 financial results is expected to be available after 1 p.m. Pacific Time on August 10, 2022, and on its website .
- 08/08/2022
|
What to Look For in a Penny Stock in 2022
- Are these tips part of your penny stocks trading strategy? The post What to Look For in a Penny Stock in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/31/2022
|
What Makes Adamis (ADMP) a New Buy Stock
- Adamis (ADMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 05/31/2022
|
Adamis Pharmaceuticals Corporation (ADMP) CEO Dennis Carlo on Q1 2022 Results - Earnings Call Transcript
- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q1 2022 Earnings Conference Call May 16, 2022 5:00 PM ET Corporate Participants Robert Uhl - ICR Westwicke Dennis Carlo - President and Chief Executive Officer David Benedicto - Chief Financial Officer Ron Moss - Chief Medical Officer David Marguglio - Chief Business Officer Conference Call Participants Operator Good evening, and welcome to the Adamis Pharmaceuticals First Quarter 2022 Financial Results Conference Call. All participants will be in a listen-only mode.
- 05/16/2022
|
Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update
- SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, May 16, 2022 at 2 p.m. Pacific Time to discuss its financial and operating results for the first quarter 2022 as well as provide a business update. The company's press release concerning its first quarter 2022 financial results is expected to be available after 1 p.m. Pacific Time on May 16, 2022, and on its website.
- 05/09/2022
|
5 Winning Stocks to Land on the Overlooked Rising P/E Trick
- Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
- 05/09/2022
|
Adamis Pharmaceuticals Corporation (ADMP) CEO Dr. Dennis Carlo on Q4 2021 Results - Earnings Call Transcript
- Adamis Pharmaceuticals Corporation (ADMP) CEO Dr. Dennis Carlo on Q4 2021 Results - Earnings Call Transcript
- 03/31/2022
|
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update
- SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Thursday, March 31, 2022 at 2 p.m. Pacific Time to discuss its financial and operating results for the fourth quarter and full year 2021 as well as provide a business update. The company's press release concerning its fourth quarter and 2021 financial results is expected to be available after 1 p.m. Pacific Time on March 31, 2022, and on its website. The company also expects to file its annual report on Form 10-K for the year ended December 31, 2021 on that date.
- 03/24/2022
|
Adamis Pharma Recalls Allergy Treatment Symjepi For Potential Manufacturing Defect
- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) voluntarily recalls certain lots of Symjepi (epinephrine) Injection 0.15 mg and 0.3 mg pre-filled single-dose syringes to the consumer level. The batches are being recalled due to the potential clogging of the needle preventing.
- 03/22/2022
|
Adamis Pharmaceuticals: Market Continues To Overlook TEMPOL's Potential To Be A Leading COVID-19 Therapeutic
- Adamis Pharmaceuticals is moving TEMPOL forward against COVID-19. The FDA recently announced that they submitted a Fast Track application for TEMPOL. TEMPOL has the potential to both prevent disease progression and reduce replication. I match TEMPOL up against contemporary COVID-19 products.
- 01/20/2022
|
3 Penny Stocks to Watch With the Stock Market Down Today
- These penny stocks climbed today, here's why The post 3 Penny Stocks to Watch With the Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/10/2022
|
Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock?
- Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.
- 12/20/2021
|
Adamis Pharmaceuticals: It's Now Or Never
- Adamis Pharmaceuticals: It's Now Or Never
- 12/01/2021
|
Top Penny Stocks For Your Under $1 List Right Now
- Check these Under $1 penny stocks out for your watchlist The post Top Penny Stocks For Your Under $1 List Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/01/2021
|
Adamis Pharmaceuticals (ADMP) Stock: Why The Price Dropped Today
- The stock price of Adamis Pharmaceuticals Corp (NASDAQ: ADMP) fell by over 15% pre-market today. This is why it happened.
- 11/23/2021
|
Adamis Pharmaceuticals Corporation (ADMP) CEO Dennis Carlo on Q3 2021 Result - Earnings Call Transcript
- Adamis Pharmaceuticals Corporation (ADMP) CEO Dennis Carlo on Q3 2021 Result - Earnings Call Transcript
- 11/23/2021
|
Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update
- SAN DIEGO, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, November 22, 2021 at 2 p.m. Pacific Time to discuss its financial and operating results for the first nine months of 2021, as well as provide a business update. The Company's press release concerning its financial results will be available after 1 p.m. Pacific Time on November 22, 2021 and on its website at www.adamispharmaceuticals.com, and the company also expects to file its quarterly reports on Form 10-Q for the quarters ended March 31, 2021, June 30, 2021 and September 30, 2021 on that date.
- 11/19/2021
|
Top Penny Stocks to Watch Making Big Moves Right Now
- If you're making a penny stocks watchlist right now, check these three small-caps out The post Top Penny Stocks to Watch Making Big Moves Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/19/2021
|
ADMP Stock: The FDA News That Has Penny Stock Adamis Pharmaceuticals Rocketing Today
- Adamis Pharmaceuticals (ADMP) stock is getting a major boost on Monday thanks to a response from the U.S. Food and Drug Administration. The post ADMP Stock: The FDA News That Has Penny Stock Adamis Pharmaceuticals Rocketing Today appeared first on InvestorPlace.
- 10/18/2021
|
Penny Stocks To Watch Today As Buying Drives ADMP, IO, LPCN & Others
- A jump in penny stock prices has retail traders cashing out on big gains. The post Penny Stocks To Watch Today As Buying Drives ADMP, IO, LPCN & Others appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/18/2021
|
Adamis Pharmaceuticals stock rockets on heavy volume after opioid overdose treatment gets FDA approval
- Shares of Adamis Pharmaceuticals Corp. ADMP, +2.73% soared 20.4% on massive volume toward an eight-month high in premarket trading Monday, after the biopharmaceutical company said Zimhi, it's high-dose naloxone injection for the treatment for opioid overdose, has been approved by the Food and Drug Administration. Trading volume spiked to 32.8 million shares, enough to make the stock the most actively traded ahead of the open, and compared with the full-day average of about 2.0 million shares.
- 10/18/2021
|
ADMP Stock: Why The Price Substantially Increased Today
- The stock price of Adamis Pharmaceuticals Corp (NASDAQ: ADMP) increased by over 35% pre-market today. This is why it happened.
- 10/18/2021
|
Adamis Receives FDA Approval for ZIMHI
- New High-Dose Naloxone Product for the Treatment of Opioid Overdose New High-Dose Naloxone Product for the Treatment of Opioid Overdose
- 10/18/2021
|
Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors
- Appointment of New Director with Significant Experience in Drug Development, Licensing and Commercialization Appointment of New Director with Significant Experience in Drug Development, Licensing and Commercialization
- 10/04/2021
|
Adamis Pharmaceuticals: TEMPOL's Near-Term And Long-Term Upside Improves As Variants Sidestep Vaccines
- Despite vaccines having some degree of efficacy against SARS-CoV-2, vaccinated patients around the world are still getting infected and capitulating to COVID-19. Antiviral drugs could be the answer.
- 09/03/2021
|
Adamis (ADMP) Begins Dosing in COVID Oral Antiviral Study
- Adamis (ADMP) starts dosing patients in phase II/III study to evaluate its oral investigational antiviral for the treatment of COVID-19.
- 09/03/2021
|
Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19
- SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection. In preclinical studies, Tempol has been shown to have antiviral, anti-inflammatory and antioxidant activity. The trial is designed to enroll 248 patients.
- 09/02/2021
|
Top Penny Stocks to Watch To Stay Ahead in September 2021
- Which penny stocks are on your September watchlist? The post Top Penny Stocks to Watch To Stay Ahead in September 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/25/2021
|
Trending Reddit Penny Stocks You Need to Know About Now
- Reddit penny stocks are in focus following the meme stock rally; here's 3 to watch The post Trending Reddit Penny Stocks You Need to Know About Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/24/2021
|
Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other Events
- SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that David C. Benedicto, who has been serving as the Company's Chief Accounting Officer, will succeed Robert O. Hopkins as Chief Financial Officer, effective immediately. Mr. Hopkins is departing to pursue new opportunities after serving the Company for the past 14 years. Management has established a comprehensive transition plan to maintain full continuity across all finance functions as Mr. Hopkins departs.
- 08/24/2021
|
Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center at Stanford Demonstrating Tempol Significantly Inhibited Multiple Cytokines from COVID-19 Patient's Cells
- Tempol: A potential home treatment for COVID-19 ( https://covid19.nih.gov/news-and-stories/tempol-potential-home-treatment-covid-19 ). Trial to begin shortly.
- 08/24/2021
|
Adamis Highlights National Institutes of Health (NIH) Article Entitled, “Tempol: A Potential Home Treatment for COVID-19”
- NIH Researchers Contend that Tempol can be taken orally and may stop the replication of the virus that causes COVID-19 NIH Researchers Contend that Tempol can be taken orally and may stop the replication of the virus that causes COVID-19
- 08/19/2021
|
Adamis Announces Agreement to Sell Portion of US Compounding Business
- Transaction Proceeds Will be Used for General Corporate Purposes and Funding Intended Acceleration of Pharmaceutical Pipeline Transaction Proceeds Will be Used for General Corporate Purposes and Funding Intended Acceleration of Pharmaceutical Pipeline
- 08/04/2021
|
Best Biotech Penny Stocks In Summer 2021? 7 For Your Watchlist
- Are these the best biotech penny stocks to watch right now? The post Best Biotech Penny Stocks In Summer 2021?
- 07/01/2021
|
Are Options Traders Betting on a Big Move in Adamis Pharmaceuticals (ADMP) Stock?
- Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.
- 06/18/2021
|
Best Penny Stocks to Buy on Robinhood? 3 For Your Morning Watchlist
- Are these Robinhood penny stocks the best to watch in 2021? The post Best Penny Stocks to Buy on Robinhood?
- 06/17/2021
|
New Strong Sell Stocks for June 15th
- CTRN, SI, ADMP, ISBA, and DGICA have been added to the Zacks Rank #5 (Strong Sell) List on June 15, 2021
- 06/15/2021
|
Adamis Pharmaceuticals: Potential COVID Drug Could Reignite Shares
- Adamis Pharmaceuticals is preparing to launch a Phase II/III study with TEMPOL in COVID-19 patients. The NIH recently reported that they found TEMPOL inhibits viral replication. I believe TEMPOL could be a leading COVID-19 therapeutic that can be employed at all stages of the infection. I provide some background on TEMPOL.
- 06/13/2021
|
Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19
- Activities Proceeding for Phase 2/3 Trial Examining the Effects of Tempol for the Treatment of COVID-19 Activities Proceeding for Phase 2/3 Trial Examining the Effects of Tempol for the Treatment of COVID-19
- 06/11/2021
|
ADMP Stock Price: Over 13% Increase Explanation
- The stock price of Adamis Pharmaceuticals Corp (NASDAQ: ADMP) increased by over 13% this morning. This is why it happened.
- 06/09/2021
|
Adamis Pharma Stock Jumps After Naloxone Injection Under FDA Review For Opioid Overdose
- The FDA has accepted for review Adamis Pharmaceuticals Corporation's (NASDAQ: ADMP) marketing application seeking approval for Zimhi, a naloxone injection for opioid overdose. The agency's target action date is November 12.
- 06/09/2021
|
Adamis Provides Update on ZIMHI™
- FDA Deems New Drug Application for ZIMHI Complete and Establishes a Target Action Date of November 12, 2021 FDA Deems New Drug Application for ZIMHI Complete and Establishes a Target Action Date of November 12, 2021
- 06/09/2021
|
Adamis Pharma Stock Jumps as NIH Sees Promise in Tempol for COVID-19
- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has highlighted that the National Institutes of Health (NIH) has identified its experimental drug, Tempol, as a potentially potent antiviral for COVID-19. According to a study of cell cultures conducted by NIH researchers, Tempol demonstrated an ability to limit SARS-CoV-2 infection by impairing the activity of a viral enzyme known as RNA replicase.
- 06/07/2021
|
ADMP Stock Price: Over 10% Increase Pre-Market Explanation
- The stock price of Adamis Pharmaceuticals Corp (NASDAQ: ADMP) increased by over 10% pre-market. This is why it happened.
- 06/07/2021
|
Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19
- NIH Researchers Contend “Tempol may be a Promising Oral Antiviral Treatment for COVID-19”
- 06/07/2021
|
ADMP Stock Price: 61.43% Increase Explanation
- The stock price of Adamis Pharmaceuticals Corp (NASDAQ: ADMP) increased by 61.43% yesterday. This is why it happened.
- 06/04/2021
|
Why Adamis Shares Are Ripping Higher Today
- Shares of Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) spiked higher in afternoon trading Thursday following some positive tidings on one of its pipeline assets. What Happened: Study of cell cultures by researchers at the National Institutes of Health showed that experimental drug Tempol may be a promising oral antiviral treatment.
- 06/03/2021
|
Adamis Pharmaceuticals Provides Business Update
- NDA for ZIMHI™ submitted to the FDA; Phase 2/3 clinical trial preparation initiated for Tempol for treatment of COVID-19 NDA for ZIMHI™ submitted to the FDA; Phase 2/3 clinical trial preparation initiated for Tempol for treatment of COVID-19
- 06/01/2021
|
Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from NASDAQ
- SAN DIEGO, May 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose (the “Company”), today announced that, as expected, on May 25, 2021, it received a standard notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“NASDAQ”) notifying the Company that, because the Company did not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the “Filing” or the “Form 10-Q”), the Company is no longer in compliance with NASDAQ Marketplace Rule 5250(c)(1), which requires timely filing of periodic reports with the Securities and Exchange Commission (the “SEC”).
- 05/28/2021
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Adamis Pharmaceuticals Corporation (ADMP) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $ADMP #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) (NASDAQ: ADMP) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Adamis investments or would like to inquire about potentially pursuing claims to recover your loss under the federal
- 05/26/2021
|
The Law Offices of Frank R. Cruz Announces Investigation of Adamis Pharmaceuticals Corporation (ADMP) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $ADMP #investors--The Law Offices of Frank R. Cruz Announces Investigation of Adamis Pharmaceuticals Corporation (ADMP) on Behalf of Investors
- 05/26/2021
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Adamis Pharmaceuticals Corporation (ADMP) on Behalf of Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $ADMP #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) (NASDAQ: ADMP) investors concerning the Company's possible violations of federal securities laws. On May 24, 2021, Adamis disclosed that "[o]n May 11, 2021, each of the Company and its US Compounding Inc. subsidiary received a grand jury subpoena from the U.S. Attorney's Office for the Southern District of New York issued in connec
- 05/25/2021
|
Investor Alert: Berman Tabacco Investigates Potential Securities Law Violations By Adamis Pharmaceuticals Corporation (ADMP) In Connection With U.S. Attorney's Criminal Investigation
- Boston, Massachusetts--(Newsfile Corp. - May 25, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential violations of the federal securities laws by Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis" or the "Company"). Adamis purports to be "a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease." The Company is based in San Diego, California.On January 29, 2021,...
- 05/25/2021
|
Adamis Pharmaceuticals Provides Update on First Quarter 2021 Financial Results Conference Call
- SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it is postponing its previously announced investor conference call scheduled to be held on Monday, May 17, 2021, at 2 p.m. Pacific Time. The company filed a Form 12b-25 with the Securities and Exchange Commission today in order to extend the due date of its Quarterly Report on Form 10-Q for the three months ended March 31, 2021, by five calendar days as permitted by Rule 12b-25 under the Securities Exchange Act of 1934, and is postponing the investor call in light of that filing delay. The company will announce a new date and time for a rescheduled investor call.
- 05/17/2021
|
Adamis Pharma Stock Gains On Resubmission Of Zimhi US Application For Opioid Overdose
- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has resubmitted a marketing application to the FDA for Zimhi, a naloxone injection product candidate intended to treat opioid overdose. "Based on FDA feedback received during our Type A meeting in April, we have resubmitted our NDA for ZIMHI, which I am confident fully addresses the issues raised in the Complete Response Letter," said President and CEO Dr. Dennis J.
- 05/17/2021
|
Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA for the Treatment of Opioid Overdose
- SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that the New Drug Application (NDA) was resubmitted to the U.S. Food and Drug Administration (FDA) for ZIMHI™, a naloxone injection product candidate intended for the treatment of opioid overdose.
- 05/17/2021
|
Adamis Pharmaceuticals Schedules First Quarter 2021 Financial Results Conference Call and Business Update
- SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that it will host an investor conference call on Monday, May 17, 2021 at 2 p.m. Pacific Time to discuss its financial and operating results for the first quarter of 2021 as well as provide a business update. The company's press release concerning its first quarter 2021 financial results will be available after 1 p.m. Pacific Time on May 17, 2021 and on its website at www.adamispharmaceuticals.com, and the company also expects to file its quarterly report on Form 10-Q for the quarter ended March 31, 2021 on that date.
- 05/12/2021
|
ADMP Stock: From $0.76 To $1.07 (40.07% Increase) Explanation
- The stock price of Adamis Pharmaceuticals Corp (NASDAQ: ADMP) increased from $0.76 to $1.07 (up 40.07%). This is why it happened.
- 05/04/2021
|
Adamis Pharmaceuticals: Upcoming Catalysts Support Speculative Buy
- Adamis Pharmaceuticals has a strong list of potential catalysts that may have a positive impact on the share price. The recent sell-off has provided me an opportunity to accumulate. Adamis has a history of botched opportunities, however, the company's efforts continue to find ways to rally share price around catalysts.
- 04/14/2021
|
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call and Business Update
- SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that it will host an investor conference call on Thursday, April 15, 2021 at 2 p.m. Pacific Time to discuss its financial and operating results for the fourth quarter and full year 2020 as well as provide a business update. The company's press release concerning its fourth quarter 2020 financial results will be available after 1 p.m. Pacific Time on April 15, 2021, on its website at www.adamispharmaceuticals.com, and the company also expects to file its annual report on Form 10-K for year ended December 31, 2020 on that date.
- 04/13/2021
|
Adamis Pharma To Resubmit Zimhi US Application For Opioid Overdose Soon
- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has provided an update on its marketing application's status seeking approval for Zimhi's high-dose naloxone injection product to treat opioid overdose. Type A meeting with the FDA was concluded.
- 04/12/2021
|
Adamis Pharmaceuticals Provides an Update on ZIMHI™
- SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the status of the company's New Drug Application (NDA) relating to its ZIMHI™ high-dose naloxone injection product intended for the treatment of opioid overdose. The company had a Type A meeting with the U.S. Food and Drug Administration (FDA) to review comments on the additional information provided by the company in response to the FDA's previous Complete Response Letter (CRL) regarding the NDA, and also to obtain input from the agency concerning the resubmission of the NDA. Adamis believes the meeting was productive and plans to resubmit the NDA for ZIMHI to the FDA within the next 45 days, absent unexpected delays. The FDA did not provide a detailed timeline for review but did indicate that it would attempt to work in an expeditious manner, acknowledging that the country is in an opioid crisis.
- 04/12/2021
|
Wait for Q4 Earnings Before Making Any Move on Adamis Pharmaceuticals Stock
- Adamis Pharmaceuticals shares were up in January on the news of its Covid-19 treatment trial, but ADMP stock has been sliding since. The post Wait for Q4 Earnings Before Making Any Move on Adamis Pharmaceuticals Stock appeared first on InvestorPlace.
- 03/30/2021
|
Will Adamis Pharmaceuticals (ADMP) Report Negative Q4 Earnings? What You Should Know
- Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 03/22/2021
|
Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the COVID-19 Challenged Hamster Model
- SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") announced today that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with the virus that causes COVID-19 (SARS-CoV-2), resulted in decreased inflammation in the lungs of animals treated with Tempol compared to controls. This is the first data demonstrating that Tempol, a novel antioxidant, can reduce inflammation in animals given the virus (SARS-CoV-2) that causes COVID-19. The group plans on submitting the publication to a peer review journal.
- 03/15/2021
|
Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19
- SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") announced today that the U.S. Food and Drug Administration (“FDA”) has completed the safety review of the Company's Investigational New Drug (“IND”) application and has concluded that Adamis may proceed with the proposed clinical investigation of Tempol for the treatment of COVID-19. The clearance to proceed follows the submission of an IND application to FDA and a Pre-IND meeting.
- 02/22/2021
|
Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate
- SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent applications relating to its ZIMHI™ high dose naloxone injection product candidate, intended for the treatment of opioid overdose, was allowed by the U.S. Patent and Trademark Office. The allowed claims describe a naloxone composition at a dose greater than or equal to five milligrams configured for administration as an injection. The company believes this patent should protect and strengthen the existing intellectual property associated with the product candidate.
- 02/17/2021
|
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
- SAN DIEGO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, announced today the pricing of its previously announced underwritten public offering of 40,540,540 shares of its common stock at a public offering price of $1.11 per share, resulting in gross proceeds of approximately $45,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the company. All shares of common stock to be sold in the public offering are being sold by Adamis.
- 01/29/2021
|
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
- SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, announced today that it intends to offer to sell shares of its common stock in an underwritten public offering. The company expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- 01/28/2021
|
Adamis Pharmaceuticals: Locking In Profits While Riding On The Back Of A Phoenix
- Adamis Pharmaceuticals finished 2020 with some Malheur with the company receiving its second CRL for ZIMHI. However, the company is a making a strong comeback thus far in 2021. Adamis plans to appeal the FDA decision on ZIMHI and has requested a Type A meeting. If all goes well, we could see ZIMHI approved in the coming months.
- 01/24/2021
|
Why Fluidigm, Seelos Therapeutics And More Are Moving Today
- Fluidigm (NASDAQ: FLDM) shares are trading higher Friday after the company announced it received the CE-IVD mark for its Advanta Dx SARS-CoV-2 RT-PCR Assay. Fluidigm manufactures life science tools focused on the analysis of single cells and industrial applications of genomics.
- 01/22/2021
|
ADMP Stock: 4 Things to Know About Adamis Pharma Today as Shares Rocket Again
- Adamis Pharma (ADMP) stock is taking off on Friday after a week of positive news for the company, including a deal with Walgreens. The post ADMP Stock: 4 Things to Know About Adamis Pharma Today as Shares Rocket Again appeared first on InvestorPlace.
- 01/22/2021
|
ADMP Stock Price Increases Over 60% Pre-Market Today: Why It Happened
- The stock price of Adamis Pharmaceuticals Corp (NASDAQ: ADMP) has increased over 60% pre-market today. This is why it happened.
- 01/22/2021
|
SYMJEPI Products Now Available in the Walgreens Prescription Savings Club, with the Lowest Prices for Epinephrine Products
- SAN DIEGO, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its SYMJEPI® (epinephrine) Injection products are now available to members of the Walgreens Prescription Savings Club program, for a discounted price of $99.99 for a two-pack, the lowest price offered for epinephrine products through the Walgreens Prescriptions Savings Club, and the lowest price for epinephrine devices on the market1.
- 01/21/2021
|
Adamis (ADMP) Submits Tempol IND for COVID-19, Shares Soar
- Adamis (ADMP) submits an investigational new drug (IND) to the FDA for the investigational use of Tempol for the treatment of COVID-19.
- 01/21/2021
|
ADMP Stock Alert: The Covid-19 Treatment News That Has Adamis Pharma Shares Soaring Today
- Adamis Pharma (ADMP) stock is taking off on Wednesday following news of its possible treatment for the novel coronavirus. The post ADMP Stock Alert: The Covid-19 Treatment News That Has Adamis Pharma Shares Soaring Today appeared first on InvestorPlace.
- 01/20/2021
|
Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19
- SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19). The submission of the IND to FDA followed a Pre-IND meeting with FDA in which FDA gave specific recommendations on Chemistry, Manufacturing and Controls (CMC) and Clinical aspects to be included in the IND. The Company plans to seek government and/or non-government funding to study the treatment and prevention of COVID-19 with Tempol.
- 01/20/2021
|
Adamis Pharmaceuticals (ADMP) Surges: Stock Moves 6.7% Higher
- Adamis Pharmaceuticals (ADMP) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
- 01/08/2021
|
Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHI
- SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that after the close of business and the U.S. markets on November 13th, it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Adamis' ZIMHI™ high dose naloxone injection product for the treatment of opioid overdose. The CRL stated that the FDA determined it cannot approve the NDA in its present form and provided recommendations needed for resubmission.
- 11/16/2020
|
Adamis Pharmaceuticals Corporation's (ADMP) CEO Dennis Carlo on Q3 2020 Results - Earnings Call Transcript
- Adamis Pharmaceuticals Corporation's (ADMP) CEO Dennis Carlo on Q3 2020 Results - Earnings Call Transcript
- 11/09/2020
|
Adamis Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update
- SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2020 and provided a business update.
- 11/09/2020
|
Adamis Pharmaceuticals Schedules Third Quarter 2020 Results Conference Call and Business Update
- SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that it will host an investor conference call on Monday, November 9, 2020 at 2:00 pm Pacific Time to discuss its financial and operating results for the third quarter of 2020 as well as provide an update on business developments and activities. The company's press release concerning its third quarter 2020 financial results will be available after 1:00 p.m. Pacific Time on November 9, 2020, on its website at www.adamispharmaceuticals.com , and the company also expects to file its quarterly report on Form 10-Q for the third quarter ended September 30, 2020, on that date.
- 11/05/2020
|
3M Co. stock rises Thursday, outperforms market
- Shares of 3M Co. inched 0.91% higher to $170.71 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...
- 10/22/2020
|
Abrasives Market 2020 - 2024: Post-Pandemic Industry Planning Structure | Technavio
- The Global Abrasives Market will grow by USD 9.15 bn during 2020-2024
- 10/22/2020
|
3M Co. stock falls Wednesday, underperforms market
- Shares of 3M Co. shed 1.04% to $169.17 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...
- 10/21/2020
|
Lionbridge International Wins 3M EMEA Supplier of the Year Award
- Lionbridge International was honored with the 2019 3M Supplier of the Year Award in recognition of the company’s contribution to 3M's business.
- 10/21/2020
|
3M Co. stock rises Tuesday, outperforms market
- Shares of 3M Co. inched 0.83% higher to $170.95 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...
- 10/20/2020
|
Diagnostic Electrodes Market Will Showcase Positive Impact During 2020-2024 | Preference for Disposable Electrodes to Boost the Market Growth | Technavio
- The Global Diagnostic Electrodes Market will grow by $ 307.09 mn during 2020-2024
- 10/20/2020
|
3M Co. stock outperforms competitors despite losses on the day
- Shares of 3M Co. slumped 0.83% to $169.55 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...
- 10/19/2020
|
Global High-Visibility Clothing Market | Demand for High-visibility Clothing From Manufacturing Industry to Boost Market Growth | Technavio
- The Global High-visibility Clothing Market will grow by $ 120.22 mn during 2020-2024
- 10/19/2020
|
Smart Parking Market | Growing Adoption of ITS to Boost the Market Growth | Technavio
- The Global smart parking market will grow by USD 5.22 bn during 2020-2024
- 10/17/2020
|
3M Co. stock outperforms market on strong trading day
- Shares of 3M Co. advanced 1.12% to $170.97 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...
- 10/16/2020
|
Construction Safety Helmets Market 2020-2024 | Size, Share, Trends, Analysis and Forecast | Research Report by Technavio
- The Global Construction Safety Helmets Market will grow by $ 110.74 mn during 2020-2024
- 10/16/2020
|
3M Co. stock rises Thursday, outperforms market
- Shares of 3M Co. inched 0.40% higher to $169.08 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...
- 10/15/2020
|
Surgical Mask Market | Increase in the Number of Surgeries Globally to Boost the Market Growth | Technavio
- The Global Surgical Mask Market will grow by USD 2.41 bn during 2020-2024
- 10/15/2020
|
3M Co. stock outperforms competitors on strong trading day
- Shares of 3M Co. rallied 1.06% to $168.40 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...
- 10/14/2020
|
America’s Top Young Scientist of 2020: 14-Year-Old Researches Spike Protein of SARS-CoV-2 Virus to Develop Novel Antiviral Drug to Combat Spread of COVID-19
- 3M (@3M) and Discovery Education (@DiscoveryEd) have named 14-year-old Anika Chebrolu from Frisco, Tex. the winner of the 2020 3M Young Scientist Chal
- 10/14/2020
|
3M Co. stock falls Tuesday, underperforms market
- Shares of 3M Co. slid 1.20% to $166.63 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling...
- 10/13/2020
|
Dividend Kings Analysis: 3M Is The Most Undervalued
- A dividend growth analysis of the 30 Dividend Kings is presented. Commerce Bancshares, Target, Stepan Company, Hormel, and Cincinnati Financial are the Top 5 Dividend Kings in the ranking model.
- 10/13/2020
|
Global Reagents Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024
- Reagents market will register an incremental spend of about $39 billion, growing at a CAGR of 6.93% during the five-year forecast period.
- 10/13/2020
|
3M Co. stock underperforms Monday when compared to competitors
- Shares of 3M Co. slid 0.38% to $168.65 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...
- 10/12/2020
|
3M Co. stock underperforms when compared to competitors despite strong trading day
- Shares of 3M Co. inched 0.95% higher to $169.30 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...
- 10/09/2020
|
2 COVID-Proof Stock Ideas For Retirees
- As we prepare for another surge of COVID-19 cases, here are two stock investment options for income-seeking investors.
- 10/09/2020
|
Capacitive Fingerprint Sensors Market Size 2020 - Business Share, Economic Impact of Key Players, Growth Investigation with Revenue, COVID-19 Impact, Opportunities and Regional Forecast to 2026
- Oct 09, 2020 (The Expresswire) --
"Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Capacitive Fingerprint Sensors...
- 10/09/2020
|
United States Hand Sanitizer Market 2020-2026: Demand for Hand Sanitizers has Increased Exponentially Due to COVID-19 - ResearchAndMarkets.com
|
Office Stationery And Supplies B2B Market to Reach $29.14 bn by 2024, 3M Co., Alibaba Group Holding Ltd., Amazon.com Inc., and WHSmith Plc., Emerge as Key Contributors to Growth | Technavio
- Technavio has been monitoring the office stationery and supplies b2b market and it is poised to grow by USD 29.14 bn during 2020-2024, progressing at a CAGR...
- 10/08/2020
|
3M Co. stock rises Thursday, still underperforms market
- Shares of 3M Co. inched 0.73% higher to $167.71 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...
- 10/08/2020
|
Healthcare Personal Protective Equipment market Growth Factors, Restraints, Trends, Competitive Landscape 2020 to 2027
- Oct 08, 2020 (Profound via COMTEX) --
The latest study collated and published by Precedence Research analyzes the historical and present-day scenario of the...
- 10/08/2020
|
COVID-19 Impact and Recovery Analysis | Water Treatment Equipment Market Procurement Intelligence Report Forecasts Spend Growth of Over USD 19 Million | SpendEdge
- The Global Water Treatment Equipment Market is poised to experience spend growth of more than USD 19 million between 2020-2024 at a CAGR of over 6.11%
- 10/08/2020
|
3M Co. stock outperforms market on strong trading day
- Shares of 3M Co. rose 2.63% to $166.49 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...
- 10/07/2020
|
Capacitive Fingerprint Sensors Market Size 2020 By Global Business Trends, Share, Future Demand, Progress Insight, Statistics, Key Regions, Prominent Players and Forecast to 2026 by ResearchReportsWorld
- Oct 07, 2020 (The Expresswire) --
Global "Capacitive Fingerprint Sensors Market" (2020-2026) discusses the report additionally centres around worldwide...
- 10/07/2020
|
Creative Financial Designs Inc. ADV Has $480,000 Position in 3M Co (NYSE:MMM)
- Creative Financial Designs Inc. ADV reduced its stake in shares of 3M Co (NYSE:MMM) by 7.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,996 shares of the conglomerate’s stock after selling 245 shares during the quarter. Creative Financial Designs […]
- 10/07/2020
|
Automotive Paints and Coatings Market will Showcase Neutral Impact during 2020-2024 | The Increasing Demand For Innovative and Specialty Products to Boost the Market Growth | Technavio
- The Global Automotive Paints and Coatings Market will grow by $ 3.96 bn during 2020-2024
- 10/07/2020
|
3M Co. stock outperforms market despite losses on the day
- Shares of 3M Co. slid 0.32% to $162.23 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling...
- 10/06/2020
|
Soft Tissue Repair Market Size, Share 2020 Global Industry Growth, Historical Analysis, Trends, Emerging Factors, Demands, Key Players, Emerging Technologies and Potential of Industry Till 2024
- Oct 06, 2020 (The Expresswire) --
Global "Soft Tissue Repair Market" report covers the present status of Market Share, CAGR, Revenue, Gross Market and the...
- 10/06/2020
|
Intelligent Parking Systems Market will Showcase Positive Impact during 2020-2024 | Increasing Use of Telematics For Car Parking to Boost the Market Growth | Technavio
- The Global Intelligent Parking Systems Market will grow by USD 5.2 bn during 2020-2024
- 10/06/2020
|
3M Co. stock rises Monday, still underperforms market
- Shares of 3M Co. rallied 1.49% to $162.75 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...
- 10/05/2020
|
3M Campaign Targets Respirator Knockoffs | PYMNTS.com
- Multinational conglomerate 3M has launched a global crackdown on counterfeit respirators and price-gouging related to a flood of knockoffs.
- 10/05/2020
|
Dow climbs 250 points on gains for shares of Caterpillar, Dow Inc.
- Shares of Caterpillar and Dow Inc. are trading higher Monday morning, propelling the Dow Jones Industrial Average into positive territory. The Dow is trading...
- 10/05/2020
|
Wet Tissue and Wipe Market Will Showcase Positive Impact During 2020-2024|Growing Concerns Regarding Hygiene to Boost the Market Growth | Technavio
- The Global Wet Tissue and Wipe Market will grow by USD 5.75 bn during 2020-2024
- 10/05/2020
|
3M Co. stock outperforms market on strong trading day
- Shares of 3M Co. inched 0.99% higher to $160.36 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...
- 10/02/2020
|
Water Filters Market Growing Demand and Industry Outlook 2020 to 2026 | Sundylee, Midea, Hanston, Flanne, 3M, Doulton, GE, Dolons, Everpure
- Oct 02, 2020 (Market Insight Reports) --
The Water Filters Market report includes an overview, which interprets value chain structure, industrial...
- 10/02/2020
|
Air Purifier Market will Showcase Negative Impact during 2020-2024 | Growing Air Pollution Levels to Boost the Market Growth | Technavio
- The Global Air Purifier Market will grow by USD 8.84 bn during 2020-2024
- 10/02/2020
|
3M Co. stock falls Thursday, underperforms market
- Shares of 3M Co. dropped 0.87% to $158.79 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...
- 10/01/2020
|
Personal Protective Equipment Market for Aerospace and Aviation Industry | Robust Growth In Global Aerospace Industry to Boost the Market Growth | Technavio
- The Global Personal Protective Equipment Market for Aerospace and Aviation Industry will grow by USD 241.49 mn during 2020-2024
- 10/01/2020
|
3M Co. stock rises Wednesday, still underperforms market
- Shares of 3M Co. inched 0.23% higher to $160.18 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...
- 09/30/2020
|
Printing and Writing Paper Market | Demand for Printed Catalogs to Boost the Market Growth | Technavio
- The Global Printing and Writing Paper Market will grow by USD 10.15 bn during 2020-2024
- 09/30/2020
|
3M Co. stock rises Monday, still underperforms market
- Shares of 3M Co. inched 0.87% higher to $161.66 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...
- 09/28/2020
|
Indoor Air Quality Meters Market- Roadmap for Recovery from COVID-19 | Increased Health Concerns to boost the Market Growth | Technavio
- The Global Indoor Air Quality Meters Market will grow by USD 1.17 bn during 2020-2024
- 09/28/2020
|
3M Co. stock falls Friday, underperforms market
- Shares of 3M Co. slid 0.09% to $160.27 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...
- 09/25/2020
|
$2.16 EPS Expected for 3M Co (NYSE:MMM) This Quarter
- Wall Street brokerages expect 3M Co (NYSE:MMM) to announce earnings of $2.16 per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for 3M’s earnings, with the lowest EPS estimate coming in at $2.12 and the highest estimate coming in at $2.20. 3M reported earnings per share of $2.58 during […]
- 09/25/2020
|
LAMEA Automotive Ceramics Market 2020-2026 by Application (Passenger Vehicles and Commercial Vehicles), & Material (Alumina, Zirconia and Other Material) - ResearchAndMarkets.com
|
3M Co. stock outperforms market on strong trading day
- Shares of 3M Co. inched 0.57% higher to $160.42 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...
- 09/24/2020
|
Europe Industrial Air Filtration Market Size, Share & Trends Analysis and Forecasts Report 2016-2019 & 2020-2027 - ResearchAndMarkets.com
|
3M Co. stock outperforms market despite losses on the day
- Shares of 3M Co. slid 1.74% to $159.51 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...
- 09/23/2020
|
Dental Laboratories Market- Roadmap for Recovery from COVID-19 | Digitization Driven By CAD/CAM Technology to Boost the Market Growth | Technavio
- The Global Dental Laboratories Market will grow by USD 10.7 bn during 2020-2024
- 09/23/2020
|
3M Co. stock rises Tuesday, still underperforms market
- Shares of 3M Co. inched 0.61% higher to $162.34 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...
- 09/22/2020
|
3M : Extends Accessible STEM Distance-learning Resources With Science at Home | MarketScreener
|
Ergonomic Computer Equipment Market- Roadmap for Recovery from COVID-19|Increasing Use Of PCs For Gaming to boost the Market Growth | Technavio
- The Global Ergonomic Computer Equipment Market will grow by USD 808.61 mn during 2020-2024
- 09/22/2020
|
3M Co. stock underperforms Monday when compared to competitors
- Shares of 3M Co. slid 4.83% to $161.36 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling...
- 09/21/2020
|
Why 3M's Latest Sales Fell Flat | The Motley Fool
- The latest monthly sales data from the industrial giant shows a dip in year-over-year growth. Here's what it means for investors.
- 09/21/2020
|
COVID-19 Recovery Analysis: Solar PV Backsheet Market | Increasing Use Of Thin-film Solar PV Modules to boost the Market Growth | Technavio
- The Global Solar PV Backsheet Market will grow by $ 2.06 bn during 2020-2024
- 09/21/2020
|
2 Industrial Stocks You Can Buy and Hold for the Next Decade | The Motley Fool
- Simply buying and forgetting these industrial stocks could make you rich .
- 09/19/2020
|
3M Co. stock falls Friday, underperforms market
- Shares of 3M Co. slipped 1.64% to $169.55 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...
- 09/18/2020
|
3M Company: Worth A Look As Recovery Takes Shape (NYSE:MMM)
- 3M management guided Q3 sales above analyst consensus estimates, as three of four segments are growing again.
- 09/18/2020
|
Research Report: Surface Disinfectants Market (2020-2024) | The Increasing Number of Health Issues Because of HAI to Boost the Market Growth | Technavio
- The Global Surface Disinfectants Market will grow by $ 387.99 mn during 2020-2024
- 09/18/2020
|
3M Co. stock outperforms competitors on strong trading day
- Shares of 3M Co. rallied 1.69% to $172.38 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...
- 09/17/2020
|
COVID-19 Recovery Analysis: Surgical Drapes Market | Growing Prevalence of HAIs to boost the Market Growth | Technavio
- The Global Surgical Drapes Market will grow by $ 536.73 mn during 2020-2024
- 09/17/2020
|
3M Co. stock rises Wednesday, outperforms market
- Shares of 3M Co. advanced 1.77% to $169.51 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...
- 09/16/2020
|
Dow's nearly 100-point jump led by gains for 3M, UnitedHealth stocks
- Shares of 3M and UnitedHealth are trading higher Wednesday morning, lifting the Dow Jones Industrial Average into positive territory. The Dow was most...
- 09/16/2020
|
Tracking Jeremy Grantham's GMO Capital Portfolio - Q2 2020 Update (MUTF:GBMFX)
- Jeremy Grantham’s 13F portfolio value increased from $11.99B to $13.47B this quarter. GMO Capital increased Alibaba Group Holding while dropping Cognizant Technology during the quarter.
- 09/16/2020
|
COVID-19 Recovery Analysis: Sanitizer Market | Increase In Hygiene Consciousness to boost the Market Growth | Technavio
- The Global Sanitizer Market will grow by $ 12.59 bn during 2020-2024
- 09/16/2020
|
3M Co. stock falls Tuesday, underperforms market
- Shares of 3M Co. slipped 1.12% to $166.57 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...
- 09/15/2020
|
Caterpillar, 3M and the Less-Than-Stellar Rebound in the Industrial Economy
- Investors got sales data from the two industrial giants, and readings on U.S. industrial production and manufacturing in the New York region. The takeaway: Buy tech.
- 09/15/2020
|
Sensata Sensing The Recovery, But Still Offers Some Upside (NYSE:ST)
- Sensata provided a meaningful boost to third quarter revenue and margin expectations, largely on the back of a stronger recovery in autos in the U.S.
- 09/15/2020
|
3M Sales Rose 2% in August | MarketScreener
|
3M's stock gains after upbeat sales outlook
- Shares of 3M Co. undefined rose 0.9% in premarket trading Tuesday, after the consumer, health care and industrial products company provided an upbeat...
- 09/15/2020
|
COVID-19 Recovery Analysis: Portable Power Tools Market | Increasing Demand for DIY Tools to Boost Market Growth | Technavio
- The Global Portable Power Tools Market will grow by $ 5.57 bn during 2020-2024
- 09/15/2020
|
3M Co. stock outperforms market on strong trading day
- Shares of 3M Co. rallied 1.38% to $168.46 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...
- 09/14/2020
|
Paints and Coatings Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024 | SpendEdge
- Paints and Coatings market will register an incremental spend of about $47 billion, growing at a CAGR of 5.23% during the five-year forecast period.
- 09/14/2020
|
Another Alabama utility sues 3M over water pollution
- Guin Water Works says it can't filter PFAS chemicals out of its drinking water and wants 3M to pay for additional filtration in the small city northwest of Birmingham.
- 09/12/2020
|
3M Co. stock rises Friday, outperforms market
- Shares of 3M Co. rallied 1.85% to $166.17 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...
- 09/11/2020
|
3M Co. stock falls Thursday, still outperforms market
- Shares of 3M Co. slid 1.54% to $163.15 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...
- 09/10/2020
|
COVID-19: Data Center Liquid Immersion Cooling Market - Roadmap for Recovery | Increase in Construction of Data Centers to Boost the Market Growth | Technavio
- The Global Data Center Liquid Immersion Cooling Market will grow by USD 2.22 bn during 2020-2024
- 09/10/2020
|
